Analysts: Funding, investment for biotechs evolving

02/8/2008 | Star-Ledger (Newark, N.J.), The

Major pharmaceutical companies have begun to pay top dollar for biotech companies with promising pipelines, and venture capitalists have poured money into early-stage biotech companies, lessening the importance of private equity groups for funding in the life sciences. As a result, mergers and acquisitions are replacing IPOs as the preferred "exit strategy" for investors in startup firms.

View Full Article in:

Star-Ledger (Newark, N.J.), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI